Brokerages Set Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) PT at $11.75

Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) has been given an average rating of “Moderate Buy” by the six research firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $11.00.

Several research analysts have weighed in on the company. JonesTrading assumed coverage on Evaxion A/S in a research report on Tuesday. They set a “buy” rating and a $10.00 price target on the stock. Maxim Group began coverage on shares of Evaxion A/S in a research note on Thursday, February 19th. They issued a “buy” rating and a $10.00 target price for the company. Lake Street Capital lowered their target price on shares of Evaxion A/S from $11.00 to $9.00 and set a “buy” rating on the stock in a report on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Evaxion A/S in a research report on Friday, January 9th. Finally, HC Wainwright reiterated a “buy” rating and issued a $16.00 price target on shares of Evaxion A/S in a research note on Monday.

Evaxion A/S News Roundup

Here are the key news stories impacting Evaxion A/S this week:

• Positive Sentiment: JonesTrading initiated coverage with a Buy recommendation, providing fresh institutional attention that likely helped the stock’s upward move. JonesTrading Begins Coverage on Evaxion
• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and maintains a $16 price target, signaling continued analyst conviction in Evaxion’s long‑term upside despite near‑term volatility. HC Wainwright Reaffirms Buy Rating
• Positive Sentiment: Management’s Q4 2025 earnings call emphasized strategic partnerships and a strong cash position, which supports funding runway and de‑risking of development programs. Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Analysts’ consensus remains a “moderate buy,” reflecting mixed views — institutional support exists but estimates vary materially across timelines. Moderate Buy Consensus
• Negative Sentiment: HC Wainwright trimmed several multi‑year EPS forecasts (FY2027–FY2030), lowering some prior estimates — this reduces near‑term earnings visibility and raises model risk. HC Wainwright Lowers Estimates
• Negative Sentiment: Lake Street Capital lowered its price target to $9.00, a nearer‑term valuation cap that could pressure sentiment if other brokers follow. Lake Street Lowers PT

Institutional Investors Weigh In On Evaxion A/S

Several hedge funds have recently bought and sold shares of the company. SmartHarvest Portfolios LLC bought a new position in Evaxion A/S during the fourth quarter worth about $72,000. Wesbanco Bank Inc. bought a new stake in Evaxion A/S in the fourth quarter valued at approximately $48,000. Finally, Northwestern Mutual Wealth Management Co. bought a new stake in Evaxion A/S in the fourth quarter valued at approximately $38,000. 11.04% of the stock is currently owned by institutional investors and hedge funds.

Evaxion A/S Price Performance

Shares of NASDAQ EVAX opened at $4.18 on Friday. The company has a debt-to-equity ratio of 0.41, a current ratio of 5.85 and a quick ratio of 5.85. The business has a 50-day moving average of $3.81 and a 200-day moving average of $4.62. The stock has a market capitalization of $34.86 million, a price-to-earnings ratio of -3.17 and a beta of 0.28. Evaxion A/S has a fifty-two week low of $1.20 and a fifty-two week high of $12.15.

Evaxion A/S (NASDAQ:EVAX) last released its earnings results on Thursday, March 5th. The company reported $0.30 earnings per share (EPS) for the quarter. As a group, sell-side analysts predict that Evaxion A/S will post -0.15 earnings per share for the current fiscal year.

About Evaxion A/S

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.